EUVIMEDEUVIMED entdecken
Crossref

1690-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Nonpeptide GLP-1 Receptor Agonist: Single- and Multiple-Ascending Dose Studies in Chinese Adults

HUAN ZHOU, YING WANG, YANGYANG GUO, FAN YANG, YUCHAN YOU, SHIRUI ZHENG, ZIHAN LIU, HUAN DENG, LIJUAN PEI, HAN HAN-ZHANG, LEI QIAN

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1690-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von HUAN ZHOU und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: IBI3032, a novel, oral non-peptide GLP-1 agonist. This first-in-human study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of IBI3032, in Chinese adults with /without overweight or obesity.

Methods

In the single-ascending dose (SAD) study (NCT07134127), 40 healthy participants (BMI 20 to 40 kg/m2) were enrolled across 4 cohorts. 8 participants each in cohort 1, 2, 4 were randomized in a 6:2 ratio to receive a single dose of IBI3032 (0.3-6 mg) or placebo (PBO). 16 participants in cohort 3 were randomized to 2 crossover sequences (under fasted and fed conditions) in an 8:8 ratio and administered IBI3032 3 mg or PBO in a 6:2 ratio. In the multiple-ascending dose (MAD) study (NCT07170319), 80 participants (BMI 24 to 40 kg/m2) were randomized into 5 cohorts (16 in each cohort), in a 12:4 ratio to receive 4 weeks of daily oral IBI3032 or PBO with dose titration to 5 different target doses. Data cutoff date was Dec 4, 2025.

Results

In SAD study, IBI3032 was well-tolerated. The most common AEs were gastrointestinal, all mild in severity; no SAE occurred. The PK profile of IBI3032 demonstrated approximately dose-proportional increases in both AUCinf and Cmax, with a geometric mean t1/2 of 43.1-52.8 h (0.3-6 mg). The observed food effect on PK was not expected to result in a clinically meaningful effect on safety and efficacy. In the ongoing MAD study, as the data cutoff date, 32 participants were enrolled (mean baseline body weight was 78.1 kg). No serve TEAEs and SAE were reported. The percentage change in mean body weight from baseline to week 4 were -8.8% and-10.7% for participants receiving IBI3032 in the 8 mg and 9 mg cohort, respectively, compared with-2.1% for those receiving PBO.

Conclusion

IBI3032 demonstrated a favourable safety, tolerability, and PK profile. Preliminary data showed significant body weight reductions with multiple doses, supporting the continued clinical development of IBI3032 as a novel oral GLP-1 agent. Disclosure H. Zhou: Consultant; Current; Innovent Biologics, Inc. Y. Wang: Consultant; Current; Innovent Biologics, Inc. Y. Guo: Consultant; Current; Innovent Biologics, Inc. F. Yang: None. Y. You: Employee; Current; Innovent Biologics, Inc. S. Zheng: Employee; Current; Innovent. Z. Liu: None. H. Deng: Employee; Current; Innovent Biologics, Inc. L. Pei: Employee; Current; Innovent Biologics, Inc. H. Han-Zhang: None. L. Qian: Employee; Current; Innovent Biologics, Inc. Funding Innovent Biologics, Inc.

Zitieren

APA

ZHOU, H., WANG, Y., GUO, Y., YANG, F., YOU, Y., ZHENG, S., LIU, Z., DENG, H., PEI, L., HAN-ZHANG, H., & QIAN, L. (2026). 1690-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Nonpeptide GLP-1 Receptor Agonist: Single- and Multiple-Ascending Dose Studies in Chinese Adults. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1690-p

Vancouver

ZHOU H, WANG Y, GUO Y, YANG F, YOU Y, ZHENG S, et al. 1690-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Nonpeptide GLP-1 Receptor Agonist: Single- and Multiple-Ascending Dose Studies in Chinese Adults. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1690-p

BibTeX
@article{ZHOU2026,
  author = {ZHOU, HUAN and WANG, YING and GUO, YANGYANG and YANG, FAN and YOU, YUCHAN and ZHENG, SHIRUI and LIU, ZIHAN and DENG, HUAN and PEI, LIJUAN and HAN-ZHANG, HAN and QIAN, LEI},
  title = {1690-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Nonpeptide GLP-1 Receptor Agonist: Single- and Multiple-Ascending Dose Studies in Chinese Adults},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1690-p}
}
Kostenlos starten →